{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplastic&page=7", "query": { "condition": "Neoplastic", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 3239, "total_pages": 324, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplastic&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplastic&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T03:57:16.195Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00022451", "title": "Tipifarnib in Treating Young Patients With Refractory Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": null, "start_date": "2001-06", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 56, "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 46 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022451" }, { "nct_id": "NCT06946017", "title": "Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Digestive Health", "Quality of Life" ], "interventions": [ { "name": "Fermented dairy protein with prebiotic fiber supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Control placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Arizona State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 114, "start_date": "2025-03-31", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06946017" }, { "nct_id": "NCT04906382", "title": "Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lynch Syndrome", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Mismatch Repair Deficiency", "Recurrent Endometrial Cancer", "Metastatic Endometrial Cancer" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Floor Backes, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2, "start_date": "2021-07-01", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906382" }, { "nct_id": "NCT00004922", "title": "Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma of Unknown Primary", "Neuroendocrine Carcinoma", "Neuroendocrine Carcinoma of the Skin" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-06", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004922" }, { "nct_id": "NCT00055562", "title": "Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Melanoma", "Neoplasm Metastasis" ], "interventions": [ { "name": "CC 5013", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2003-01", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 25, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055562" }, { "nct_id": "NCT04131062", "title": "Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lynch Syndrome" ], "interventions": [ { "name": "Electronic Consent (iPad)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Geisinger Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 703, "start_date": "2019-11-01", "completion_date": "2022-05-19", "has_results": false, "last_update_posted_date": "2022-12-27", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 1, "location_summary": "Danville, Pennsylvania", "locations": [ { "city": "Danville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04131062" }, { "nct_id": "NCT04995523", "title": "A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "AZD2936", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 212, "start_date": "2021-09-14", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 3, "location_summary": "Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04995523" }, { "nct_id": "NCT03494569", "title": "Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia in Remission", "Hematopoietic Cell Transplantation Recipient", "Minimal Residual Disease", "Myelodysplastic Syndrome", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Total Marrow Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 36, "start_date": "2018-07-06", "completion_date": "2027-09-07", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03494569" }, { "nct_id": "NCT01079741", "title": "Safety Study of Adjuvant Vaccine to Treat Melanoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "NY-ESO-1 protein; Poly-ICLC; Montanide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nina Bhardwaj", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2010-09", "completion_date": "2013-03-11", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01079741" }, { "nct_id": "NCT04329494", "title": "PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Malignant Uterine Neoplasm", "Metastatic Appendix Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Malignant Neoplasm in the Peritoneum", "Metastatic Malignant Solid Neoplasm", "Metastatic Ovarian Carcinoma", "Pathologic Stage IV Gastric Cancer AJCC v8", "Peritoneal Carcinomatosis", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Stage IV Appendix Carcinoma AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Appendix Carcinoma AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Appendix Carcinoma AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Stage IVC Appendix Carcinoma AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Intraperitoneal Chemotherapy", "type": "DEVICE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-08-21", "completion_date": "2028-01-05", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-19T03:57:16.195Z", "location_count": 3, "location_summary": "Duarte, California • Jacksonville, Florida • Greenlawn, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Greenlawn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04329494" } ] }